Coramaze invented the Tripair® valve repair system for treatment of functional Tricuspid Regurgitation
2017
Year invested
Fund I
MTIP Fund
Israel, Germany
Location
Active Investment
Investment status
Heart Valves
Segment
CoramazeTechnologies develops Tripair®, a valve repair system designed for the treatment of functional Tricuspid Regurgitation (fTR) in heart failure patients. fTR represents a high unmet medical need, with a large majority of patients left with no therapeutic option. Coramaze’s minimally invasive procedure aims to improve quality of life and reduce morbidity.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.